Document Detail


Haemodynamic impact of diuretic therapy in chronic heart failure.
MedLine Citation:
PMID:  7954533     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
An immediate improvement in haemodynamic variables and cardiac performance is achieved in chronic heart failure following diuretic therapy, primarily due to reductions in plasma and extracellular fluid volumes. Humoral markers of these alterations are increased plasma renin, angiotensin and aldosterone levels; these increase maximally over the first week of treatment but attenuate during sustained therapy. There are reciprocal alterations in plasma alpha-atrial natriuretic peptide levels. These findings suggest that the initial volume contraction is maintained, though somewhat attenuated, during chronic therapy. The neurohumoral consequences of diuretic therapy are of particular interest in heart failure, as they may contribute to diuretic resistance. Activation of the renin-angiotensin system favours the proximal tubular reabsorption of sodium and water, which may result in dilutional hyponatraemia. Diuretics have both direct vascular and non-vascular (volume-dependent) haemodynamic actions. Together these substantially reduce the left heart filling pressure (-29%) with a consequent fall in cardiac output (-10%). Systemic vascular resistance initially increases but subsequently normalizes, allowing cardiac output to return towards control values. Haemodynamic tolerance to diuretics does not usually occur during sustained oral therapy; additionally, echocardiographic contractility indices and exercise capacity may increase. The vasodilator activity of the diuretics is due to prostaglandin release; the initial pressor action is due to activation of the renin-angiotensin system. Direct pulmonary vasodilatation with improved pulmonary compliance remains an interesting possibility. Over the longer term, substantial reductions in left heart filling pressure during exercise occur at unaltered cardiac output. The impact of diuretic therapy on the underlying myocardial disease process is unknown.(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
B Silke
Related Documents :
14986083 - Severe hypertension and massive proteinuria in a newborn with renal artery stenosis.
15466263 - Intravenous delivery of pth/pthrp type 1 receptor cdna to rats decreases heart rate, bl...
22128243 - Elevated pressure downregulates zo-1 expression and disrupts cytoskeleton and focal adh...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Cardiology     Volume:  84 Suppl 2     ISSN:  0008-6312     ISO Abbreviation:  Cardiology     Publication Date:  1994  
Date Detail:
Created Date:  1994-12-28     Completed Date:  1994-12-28     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  1266406     Medline TA:  Cardiology     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  115-23     Citation Subset:  IM    
Affiliation:
Department of Therapeutics and Pharmacology, Queen's University of Belfast, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Diuretics / pharmacology*,  therapeutic use
Heart Failure / drug therapy*,  physiopathology
Hemodynamics / drug effects*
Humans
Renin-Angiotensin System / drug effects
Chemical
Reg. No./Substance:
0/Diuretics

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pharmacokinetics and pharmacodynamics of torasemide in congestive heart failure.
Next Document:  Clinical and haemodynamic effects of long-term treatment with torasemide in congestive heart failure...